From: Randomized crossover trial of a modified ketogenic diet in Alzheimer’s disease
First treatment period | Second treatment period | All patients | Treatment effect | ||||
---|---|---|---|---|---|---|---|
Ketogenic-usual diet (n = 13) | Usual-ketogenic diet (n = 13) | Ketogenic-usual diet (n = 13) | Usual-ketogenic diet (n = 13) | Ketogenic diet (n = 26) | Usual diet (n = 26) | ||
Cognition (ACE-III) | |||||||
Baseline | 69.3 ± 15.2 | 71.1 ± 15.5 | 72.5 ± 20.3 | 70.3 ± 19.3 | 69.8 ± 17.0 | 71.8 ± 17.7 | + 2.12 ± 8.70 (P = 0.24) |
Change at week 6 | + 2.82 ± 7.55 | + 0.46 ± 5.32 | −1.96 ± 6.02 | − 0.03 ± 2.49 | + 1.39 ± 5.69 | − 0.75 ± 5.70 | |
Change at week 12 | + 3.45 ± 4.44 | − 1.77 ± 6.04 | −1.92 ± 7.26 | −2.90 ± 4.57 | + 0.28 ± 5.48 | −1.84 ± 6.55 | |
Daily function (ADCS-ADL) | |||||||
Baseline | 66.7 ± 7.7 | 65.8 ± 8.2 | 64.5 ± 13.2 | 62.3 ± 13.0 | 64.5 ± 10.7 | 65.2 ± 10.8 | + 3.13 ± 5.01 (P = 0.0067) |
Change at week 6 | + 1.06 ± 3.53 | − 0.85 ± 2.51 | + 0.04 ± 2.70 | + 0.30 ± 2.08 | + 0.68 ± 2.87 | −0.40 ± 2.59 | |
Change at week 12 | + 0.22 ± 3.63 | −4.46 ± 4.58 | − 1.54 ± 2.82 | + 0.04 ± 3.07 | + 0.13 ± 3.30 | −3.00 ± 4.00 | |
Quality of life (QOL-AD) | |||||||
Baseline | 33.8 ± 5.6 | 33.9 ± 5.8 | 34.1 ± 8.5 | 31.8 ± 7.3 | 32.8 ± 6.4 | 34.0 ± 7.1 | + 3.37 ± 6.86 (P = 0.023) |
Change at week 6 | −0.26 ± 3.39 | + 0.46 ± 3.28 | + 0.43 ± 7.56 | + 1.71 ± 4.37 | + 0.73 ± 3.96 | + 0.45 ± 5.71 | |
Change at week 12 | + 2.86 ± 4.64 | −1.15 ± 5.41 | + 0.31 ± 3.68 | + 3.03 ± 7.52 | + 2.95 ± 6.12 | −0.42 ± 4.60 |